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Abstract
The analysis of in vitro anti-malarial drug susceptibility testing is vulnerable to the effects of different statistical approaches
and selection biases. These confounding factors were assessed with respect to pfmdr1 gene mutation and amplification in
490 clinical isolates. Two statistical approaches for estimating the drug concentration associated with 50% effect (EC50) were
compared: the commonly used standard two-stage (STS) method, and nonlinear mixed-effects modelling. The in vitro
concentration-effect relationships for, chloroquine, mefloquine, lumefantrine and artesunate, were derived from clinical
isolates obtained from patients on the western border of Thailand. All isolates were genotyped for polymorphisms in the
pfmdr1 gene. The EC50 estimates were similar for the two statistical approaches but 15–28% of isolates in the STS method
had a high coefficient of variation (.15%) for individual estimates of EC50 and these isolates had EC50 values that were 32 to
66% higher than isolates derived with more precision. In total 41% (202/490) of isolates had amplification of pfmdr1 and
single nucleotide polymorphisms were found in 50 (10%). Pfmdr1 amplification was associated with an increase in EC50 for
mefloquine (139% relative increase in EC50 for 2 copies, 188% for 3+ copies), lumefantrine (82% and 75% for 2 and 3+ copies
respectively) and artesunate (63% and 127% for 2 and 3+ copies respectively). In contrast pfmdr1 mutation at codons 86 or
1042 were associated with an increase in chloroquine EC50 (44–48%). Sample size calculations showed that to demonstrate
an EC50 shift of 50% or more with 80% power if the prevalence was 10% would require 430 isolates and 245 isolates if the
prevalence was 20%. In conclusion, although nonlinear mixed-effects modelling did not demonstrate any major advantage
for determining estimates of anti-malarial drug susceptibility, the method includes all isolates, thereby, potentially
improving confirmation of candidate molecular markers of anti-malarial drug susceptibility.
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Introduction
In vitro drug susceptibility assays provide a means of assessing
anti-malarial drug activity. These assays are important tools for
monitoring anti-malarial drug resistance, determining the rela-
tionship between parasite genetic polymorphisms and drug
susceptibility, and quantifying the potency of novel compounds.
A variety of methodological approaches have been developed and
applied to assessment of laboratory adapted strains of Plasmodium
as well as field isolates of P. falciparum and P. vivax [1–3].
Established assays vary, but in general define a parasites’ drug
susceptibility by measurements of growth or development ex vivo in
the constant presence of varying drug concentrations, usually
generated by doubling dilutions of the drug under investigation.
The standard statistical analysis of such assays focuses on fitting
separate nonlinear regression equations to each isolate’s concen-
tration-effect data, using a nonlinear Sigmoid Emax equation,
deriving four measures: the minimum and maximum effect, the
slope (sigmoidicity) of the effect-concentration curve, and the drug
concentration that achieves 50% of the maximum effect (termed
the EC50). The isolate-specific estimates of these parameters are
then combined to calculate summary statistics that describe the
population distribution. However this approach, referred to as the
standard two-stage (STS) method [4], is vulnerable to a variety of
selection biases [5]. Importantly the estimates of highly resistant
isolates, often the most interesting parasites, are intrinsically less
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precise and thus often rejected [6]. In the case of laboratory
isolates drug susceptibility assays can be repeated, however, in field
studies repetition of the assay with revised drug concentrations is
often not feasible from a fresh sample unless isolates are adapted to
continuous culture, a process which may increase selection bias
further. Simply excluding these extreme isolates as unreliable
skews the population estimates towards a lower population mean
EC50.
Nonlinear mixed-effects modelling is an alternative statistical
approach for analysing repeated measurement data [7]. When
applied to the analysis of in vitro drug susceptibility data,
information from all of the isolates is analysed simultaneously.
Estimates of the population mean values for each of the model
parameters are derived, as well as the between-isolate variance of
each parameter and the overall within-isolate variance. Although
routinely used in sparsely sampled pharmacokinetic studies [8,9],
its application to the analysis of data from in vitro studies is limited.
On the western border of Thailand multidrug resistance in
P.falciparum has been shown to correlate with polymorphisms of
pfmdr1; gene amplification being associated with reduced sensitivity
to mefloquine, lumefantrine and artemisinin derivatives [10,11],
whereas single nucleotide polymorphisms are associated with
chloroquine resistance [12]. In this study, we have pooled a large
collection of carefully characterised field isolates from Thailand, to
review the in vitro – molecular correlates and intra-assay variation
using the STS method and nonlinear mixed-effects modelling. The
comparison is restricted to four anti-malarial drugs, chloroquine,
mefloquine, lumefantrine and artesunate, to evaluate if the more
complex and comprehensive method of nonlinear mixed-effects
modelling, provides important additional information on the
in vitro - molecular correlation of antimalarial drug resistance and
specifically whether it provides increased statistical power for
detecting shifts in in vitro susceptibility of subgroup parasite
populations.
Materials and Methods
Clinical Isolates
Fresh parasite isolates were obtained from patients with acute P.
falciparum malaria attending clinics of the Shoklo Malaria Research
Unit (SMRU), between 1993 and 2005. The SMRU clinics are all
located along 100 km of the Thai-Myanmar border. Isolates were
collected from primary infections with a parasite density of at least
5 parasites/1,000 red blood cells. Venous blood (5 ml) was
collected into a sterile VacutainerH tube containing 0.05 ml
Potassium-EDTA. Samples were kept at room temperature before
being (within the next 4 to 6 hrs) transported to the main
laboratory, where they were set up in continuous culture
immediately. The fresh parasite isolate samples were obtained as
part of prospective clinical evaluations of anti-malarial drug
therapy. Written informed consent translated in the patient own
language was obtained from each participant, whose signature was
witnessed. The studies were approved by the Ethics Committee of
the Faculty of Tropical Medicine, Mahidol University.
In vitro Drug Assay
In vitro drug susceptibility was determined by the hypoxanthine
uptake inhibition assay, the details of which have been described
previously [13]. Briefly, fresh isolates were adjusted to an optimum
density of 0.5–1.0% IRBC and a haematocrit of 1.5% using fresh
washed group O erythrocytes and complete RPMI-1640 medium
with 10% heat-inactivated AB sera. The suspension of infected
erythrocytes was dispensed into the wells of a standard microtitre
plate containing duplicate serial dilutions of the antimalarial drugs.
Serial dilutions for the majority of isolates were measured as the
following: 1646.6 to 1.62 nM for mefloquine, 87.0 to 0.044 nM
for artesunate, 10255.9 to 10.02 nM for chloroquine, 235.8 to
2.40 nM for lumefantrine; and were made in complete RPMI
medium. All drug concentrations, including drug-free controls,
were generated in duplicate in 96-well tissue culture plates. The
drug-plates were made in bulk and stored at 280uC until use.
Following incubation for 24 h, the microtitre plates were pulsed
with [3H] hypoxanthine isotopic solution to each well. After a
further 18 h incubation, the plates were then harvested. The
reproducibility of the EC50 measurements was assessed regularly
using cloned K1 isolates of P.falciparum.
Table 1. Distribution of EC50 and slope (c) values for concentration-effect curves of chloroquine, mefloquine, lumefantrine and
artesunate, derived from the two statistical modelling approaches: standard two-stage method and nonlinear mixed-effects
modelling.
EC50 Slope
Anti-malarial
drug Method
Estimate
(nM)
95% reference
range
Estimate
(loge nM)
SD
(loge nM) Estimate
95% reference
range
Estimate
(loge units)
SD
(loge units)
Chloroquine (n = 421) STS 230.3{ 63.8, 831.3` 5.44 0.66 3.75{ 1.47, 9.53` 1.32 0.48
NLME 240.7 68.6, 844.0* 5.48 0.64 4.14 1.85, 9.25* 1.42 0.41
Mefloquine (n = 460) STS 67.2{ 10.0, 450.5` 4.21 0.97 2.82{ 1.07, 7.45` 1.04 0.50
NLME 70.4 11.3, 435.6* 4.25 0.93 3.10 1.39, 6.92* 1.13 0.41
Lumefantrine (n = 324) STS 38.6{ 6.4, 234.6` 3.65 0.92 2.47{ 0.86, 7.09` 0.90 0.54
NLME 40.7 7.2, 228.0* 3.71 0.88 2.73 1.22, 6.10* 1.00 0.41
Artesunate (n = 474) STS 2.75{ 0.48, 15.7` 1.01 0.89 5.85{ 1.76, 19.46` 1.77 0.61
NLME 2.58 0.44, 15.32* 0.95 0.91 5.86 1.70, 20.10* 1.77 0.63
STS – standard two-stage method; NLME – nonlinear mixed-effects modelling; SD – standard deviation for between-isolate variability.
{Geometric mean.
`Calculated from estimated mean & SD (loge scale) and converted to original scale.
*95% prediction interval.
doi:10.1371/journal.pone.0069505.t001
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Molecular Analysis of pfmdr1
Details of the methods used to determine pfmdr1 copy number
have been described previously [14]. In summary, pfmdr1 copy
number was assessed by quantitative PCR (ABI sequence detector
7700 or 7900HT; Applied BiosystemsTM) and all reactions were
performed in triplicate or quadruplicate. DNA for the molecular
analysis of pfmdr1 copy number was available from whole blood or
from 50 mL of capillary blood transferred to filter paper. Genetic
variants of pfmdr1 occur either through single nucleotide polymor-
phisms at key loci or amplification of the whole gene resulting in
increased copy number. In Thai isolates the latter process occurs
almost exclusively in parasites of the wild type pfmdr1 [11,15]. For
this reason parasites were classified into the five genotypes: 1)
Single copy with the wild type allele including 86N and 1042N; 2)
Single copy number with the 86Y mutation alone, 3) Single copy
number with 1042D mutation; 4) Double copy number (all 86N
and 1042N), 5) Triple or more copy number (also all 86N and
1042N).
Statistical Analysis
The initial data set included all assays in which both in vitro and
molecular data were available. The analysis was restricted to four
anti-malarial drugs: chloroquine, mefloquine, lumefantrine and
artesunate.
The nonlinear equation fitted to the data was the following
sigmoid inhibitory effect model:
E~Emax{(Emax{E0)|
Cc
CczEC
c
50
 
ð1Þ
E represents the percentage of uptake of hypoxanthine and was
normalized to the control wells using the following equation:
E~
Eraw{Ebackground
Econtrol{Ebackground
Eraw is the absolute value for the uptake of hypoxanthine in the
drug well, compared to that in the control well (Econtrol) and that of
the background radiation (Ebackground ) from two wells containing
only infected red blood cells. Maximum inhibition occurs when
there is no uptake of hypoxanthine (no growth), that is, E equals 0.
In equation 1, E0 represents minimum percent growth, Emax is the
maximum percent growth, EC50 is the concentration of the drug
required to inhibit 50 percent of the control parasites’ hypoxan-
thine uptake, C represents the drug concentration and c is the
slope of the curve.
Initially, the data were analysed using the STS method. For
stage 1, the sigmoid inhibitory effect model (equation 1) was fitted
to each individual isolate’s effect-concentration data by the
application of nonlinear regression using the software package
WinNonlin (PharsightTM Corporation).
Isolates with predicted curves where the maximum uptake of
hypoxanthine was greater than 125% or less than 75% and/or the
minimum uptake of hypoxanthine was greater than 25% or less
than 225% were excluded from all further analyses. Although
some laboratories exclude isolates in which the coefficient of
variation for the EC50 (i.e. standard error divided by EC50 estimate
from nonlinear regression of effect-concentration curve) is greater
than 15%, in the current study these isolates were included in the
overall analysis.
The individual isolate estimates of EC50 and slope (c), and the
coefficients of variation (standard error divided by estimate) for
each estimate were saved in a data file (see File S1). For stage 2 of
the analysis, the distribution of EC50 and slope for the study
population were summarised by calculating the geometric mean
and 95% reference range of the individual estimates of EC50 and
slope.
Second, the data were analysed using nonlinear mixed-effects
modelling. Effect-concentration data from all isolates were
analysed simultaneously using equation 1, where for isolate i and
drug concentration j, the sigmoid inhibitory effect Eij was given as:
Eij~Emax :i{(Emax :i{E0)|
C
c:i
ij
C
c:i
ij zEC
c:i
50:i
" #
ð2Þ
where
Emax :i~Emaxzgi:Emax
Table 2. Distribution of EC50 values derived from the standard two-stage method for concentration-effect curves of chloroquine,
mefloquine, lumefantrine and artesunate.
Anti-malarial
drug
Coefficient of variation of
isolate-specific estimates of EC50
Number of
isolates (%)
EC50 estimate
(nM){
95% reference
range` p-value
Chloroquine (n = 421) CV ,15% 356 (84.6) 220.0 67.7, 715.1 0.001
CV $15% 65 (15.4) 295.4 55.1, 1585.0
Mefloquine (n = 460) CV ,15% 386 (83.9) 63.7 10.8, 374.9 0.007
CV $15% 74 (16.1) 88.8 7.9, 994.5
Lumefantrine (n = 324) CV ,15% 245 (75.6) 34.9 6.9, 176.8 ,0.001
CV $15% 79 (24.4) 52.7 6.0, 466.7
Artesunate (n = 474) CV ,15% 342 (72.1) 2.42 0.43, 13.45 ,0.001
CV $15% 132 (27.9) 3.87 0.76, 19.68
CV – coefficient of variation;
{Geometric mean.
`Calculated from estimated mean & SD (loge scale) and converted to original scale.
doi:10.1371/journal.pone.0069505.t002
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Figure 1. Estimated concentration-effect relationship (via nonlinear mixed-effects modelling) for chloroquine, mefloquine,
lumefantrine and artesunate, by genotype grouping.
doi:10.1371/journal.pone.0069505.g001
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EC50:i~EC50| exp (gi:EC50)
ci~c| exp (gi:c)
Emax, EC50 and c represent the population means and gi, Emax, gi,
EC50 and gi, c are normally distributed random-effects with mean
zero and variances VEmax, VEC50 and Vc, respectively. Thus the Vs
represent the between-isolate variability for these parameters,
reflecting a variety of confounders, including methodological, host
and parasite factors that may retain inherent influence within the
assay. Between-isolate variability in EC50 and c was assumed to be
lognormally distributed; a reasonable assumption since the
individual isolate parameter estimates displayed positively skewed
distributions and these parameters should always have positive
values. Between isolate variability in Emax was assumed to be
normally distributed since the individual parameter estimates
displayed a symmetric distribution. Between isolate variability for
E0 was not incorporated into the model.
Residual variability was modelled with additive and propor-
tional components:
Eij~E

ijzE

ij|eij:propzeij:add ð3Þ
Eij and E
*
ij are the observed and predicted normalised percentage
uptake of hypoxanthine, respectively, and the residual variability
components ei,j, prop and ei,j,add were assumed to be normally
distributed with mean zero and the respective variances s2prop and
s2add. The nonlinear mixed-effects analysis was performed in
NONMEM Version 7.1 (Icon Development Solutions, Ellicott
City, MD, USA) in conjunction with the pearl-speaks-NONMEM
program (PsN Version 3.5.3; [16,17]), and the corresponding
results were compared with the results obtained from the STS
approach.
Lastly, a second nonlinear mixed-effects analysis was performed
to estimate the effect of genotype grouping on the parameters,
EC50 and c. Equations 2 and 3 were used again to analyse data
from all isolates simultaneously, but with the following modifica-
tions to equation 2:
EC50:i~EC50(1zh1|X1zh2|X2zh3|X3zh4|X4):
exp (gi:EC50)
ci~c(1zh5|X1zh6|X2zh7|X3zh8|X4): exp (gi:c)
X1–X4 are binary indicators (0 = no, 1 = yes) for an isolate with a
single copy with mutation at position 86Y (X1), single copy with
mutation at position 1042D (X2), two copies (all wild types; X3) or
three or more copies (all wild types; X4), respectively, and h1–h4
represent the difference in EC50 between the groups indicated by
X1–X4 (respectively) and the group with a single copy with wild
type alleles at positions 86N and 1042N. A similar description can
be made for h5–h8 for c.
Table 3. Effect of genotype grouping of Pfmdr1 on EC50 for chloroquine, mefloquine, lumefantrine and artesunate using nonlinear
mixed-effects modelling.
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Genotype 5
Single Copy Single Copy Single Copy Double Copy Triple+ Copy
EC50 WT
{ 86Y` 1042D` 86N/1042N` 86N/1042N`
Chloroquine #
Percent change Reference category 44 (14,73) 48 (24,100) 210 (223, 3) 210 (228, 7)
Estimated value (nM) 242 (223, 260) 347 (275,419) 359 (233, 483) 217 (184, 248) 217 (174, 260)
No. of isolates 212 20 19 113 57
Mefloquine
Percent change Reference category 259 (272, 246) 242 (267, 217) 139 (102,175) 188 (126,250)
Estimated value (nM) 53.0 (48.0, 58.1) 21.7 (14.7,28.7) 30.9 (17.6,44.1) 126.3 (107.0,145.9) 152.6 (119.8,185.4)
No. of isolates 230 25 24 118 63
Lumefantrine
Percent change Reference category 231 (262,0) 257 (276, 237) 82 (46,119) 75 (28,122)
Estimated value (nM) 35.7 (31.4,39.9) 24.6 (13.6,35.7) 15.5 (8.5,22.5) 65.0 (51.8,78.1) 62.4 (45.6,79.2)
No. of isolates 183 16 17 83 25
Artesunateˆ
Percent change Reference category 217 (239,6) 38 (227,102) 63 (35,92) 127 (74,169)
Estimated value (nM) 2.3 (2.1,2.6) 1.8 (1.3,2.3) 3.1 (1.6,4.4) 3.6 (3.1,4.2) 4.9 (3.9,6.2)
No. of isolates 234 24 24 123 69
95% confidence intervals in brackets; {Reference group; #Emax fixed to 0.98;
ˆE0 fixed to 0.01.
Between2isolate variance estimate (standard errors) for EC50: 2 0.39(0.026) chloroquine, 0.56(0.043) mefloquine, 0.63(0.050) lumefantrine, 0.67(0.048) artesunate.
Within-isolate variance estimates (standard errors) are:-.
proportional – 0.013(0.0018) chloroquine, 0.010(0.0011) mefloquine, 0.019(0.0020) lumefantrine, 0.025(0.0037) artesunate;
additive – 0.001(0.0002) chloroquine, 0.001(0.0001) mefloquine, 0.0009(0.0002) lumefantrine, 0.0007(0.0002) artesunate.
doi:10.1371/journal.pone.0069505.t003
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Simulation Study Comparing Methods for Detecting
in vitro Correlates
To compare the STS and nonlinear mixed-effects modelling
approaches for detecting genotype grouping effects on EC50 in
studies with smaller sample size, a simulation study was performed
for mefloquine and lumefantrine (these two anti-malarials were
selected because they vary in terms of the magnitude of the effect
of pfmdr1 copy number on EC50). To do this a random sample of
25, 50 or 100 isolates was drawn from the entire data set available
for each of these drugs. For these isolates, the mean EC50 (derived
from either STS or nonlinear mixed-effects modelling) was
compared between isolates that displayed a single copy (geno-
type1, above) versus two or more copies (genotypes 4 and 5 above).
The prevalence of two or more copies was 39% for the population
of isolates for mefloquine and 33% for the lumefantrine isolates.
This process was repeated 100 times, and was considered a
‘‘pseudo-simulation’’ study since step 1 involved drawing random
samples from the observed data rather than simulating the data
from a statistical model. The proportion of runs where the
genotype grouping effect on EC50 was detected (via the likelihood
ratio test and defined as a p-value ,0.05) was compared between
the nonlinear mixed-effects modelling and STS approaches for the
specified number of isolates (i.e. 25, 50 or 100).
Results
In total 490 isolates were available for statistical analysis of at
least one of the anti-malarial drugs tested. Concentration-effect
data could be derived from a total of 421 (86%) isolates for
chloroquine, 460 (94%) isolates for mefloquine, 324 (66%) isolates
for lumefantrine, and 474 (97%) isolates for artesunate. The
median number of observations per isolate across all drugs was 22
[range 7 to 44].
Comparison of Standard Two-stage Method and
Nonlinear Mixed-effects Modelling
Comparison of the two analytical approaches (STS method and
nonlinear mixed-effects modelling) demonstrated that overall the
population derived estimates of EC50 and slope were similar (see
Table 1). Nonlinear mixed-effects modelling yielded slightly lower
between-isolate standard deviations (SDs) of the estimates of EC50
and slope, with the exception of artesunate, where the SDs were
marginally higher.
The proportion of EC50 estimates from the STS approach with
a coefficient of variation (CV) .15% was 15.4% (65/421) for
chloroquine, 16.1% (74/460) for mefloquine, 24.4% (79/324) for
lumefantrine and 27.9% (132/474) for artesunate. Isolates with a
higher CV had significantly higher EC50 values compared to those
with CVs below or equal to the 15% threshold (see Table 2).
Estimation of In Vitro Molecular Correlates Using
Nonlinear Mixed-effects Modelling
Of the 490 isolates available for statistical analysis, the
prevalence of the pfmdr1 genotype groupings was 49% for single
copy wild type (Genotype 1), 5% for single copy number with
mutation at position 86Y (Genotype 2), 5% for single copy number
with mutation at either positions 1042D (Genotype 3), and 26%
for amplification with two copies (Genotype 4) and 15% for three
or more copies (Genotype 5). The prevalence for mutation at
position 1034C was 3% (5 isolates out of 187).
Single copy number with mutation at position
86Y. Isolates with a single copy number with mutation at
position 86Y were associated with a decrease in the EC50 value for
mefloquine, lumefantrine and artesunate, compared to those with
single copy wild type alleles 86N and 1042N. The magnitude of
this decrease ranged from 59% for mefloquine, a 31% reduction
for lumefantrine and a 17% reduction for artesunate (see Table 3,
Figure 1). Conversely, a single copy number with mutation at
position 86Y was associated with a relative increase of 44% for the
EC50 value of chloroquine. In contrast the slope of the effect-
concentration curve did not differ significantly for these molecular
comparisons (File S2).
Single copy number with mutation at position
1042D. For mefloquine and lumefantrine, isolates with a single
copy number with mutations at positions 1042D (Genotype 3)
were associated with a decrease in the EC50 value compared with
single copies of wild type (Genotype 1). The magnitude of this
decrease was 42% for mefloquine (population mean estimate of
30.9 versus 53.0 nM) and 57% for lumefantrine (population mean
estimate of 15.5 versus 35.7 nM) (see Table 3, Figure 1).
Conversely, Genotype 3 variants were associated with a relative
increase of 48% for the EC50 value of chloroquine (population
mean estimate of 359 versus 242 nM). For artesunate a relative
increase in the EC50 estimate was also observed, however, the 95%
confidence interval ranged from a relative decrease of 27% to a
relative increase of 102%. As with the variants at codon 86Y,
minimal changes in the slope of the concentration-effect profile
with the 1042D variant were observed (File S2).
Table 4. Results from the pseudo-simulation study
comparing the standard two-stage and nonlinear mixed-
effects modelling approaches for detecting a binary genotype
grouping effect on EC50 in studies with 25, 50 or 100 isolates.
Anti-malarial
Analytical
approach
Number of Isolates
Assessed
25 50 100
Mefloquine{,` STS 85%ˆ 100% 100%
STS (CV
#15%)e
85% 98% 100%
NLME 87% 100% 100%
Lumefantrine{* STS 49% 77% 98%
STS (CV
#15%)e
42% 64% 93%
NLME 46% 74% 97%
STS - standard two-stage; NLME - nonlinear mixed-effects modelling; CV –
coefficient of variation.
Pˆercentage of runs where shift in EC50 was detected according to parasite
genotype via the likelihood ratio test.
{Genotype was grouped as a single wild type (reference category) versus wild
type with two or more copies.
`For the entire dataset (the assumed population) of isolates with wild type
alleles exposed to mefloquine (230 (50%) isolates with a single copy & 181
(39%) with two or more copies), the estimated genotype effect on EC50 was 2.60
(ratio of geometric means; 95% CI 2.24 to 3.02) from the standard two-stage
approach and 2.55 fold (95% CI 2.32 to 2.78) from the nonlinear mixed-effects
modelling approach.
*For the entire dataset (the assumed population) of isolates with wild type
alleles exposed to lumefantrine (183 (56%) isolates with a single copy & 108
(33%) with two or more copies), the estimated genotype effect on EC50 was 1.91
(ratio of geometric means; 95% CI 1.57 to 2.32) from the standard two-stage
approach and 1.82 fold (95% CI 1.43 to 2.22) from the nonlinear mixed-effects
modelling approach.
eOnly includes those isolates where the coefficient of variation (CV) of the EC50
estimate in the first stage of the STS analysis was #15% (,84% of total sample
for mefloquine & ,76% for lumefantrine).
doi:10.1371/journal.pone.0069505.t004
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Pfmdr1 Amplification. Isolates with two or more copies of
pfmdr1 were all ‘‘wild type’’ (86N and 1042N). Those with two or
three-or-more copies had significantly higher EC50 values for
mefloquine (139% and 188%, respectively), lumefantrine (82%
and 75%, respectively) and artesunate (63% and 127%, respec-
tively) compared with isolates with a single copy wild type (see
Table 3, Figure 1). In contrast the mean EC50 for chloroquine was
similar for isolates irrespective of their copy numbers (Table 3).
Compared to single copy isolates, those with two or more copies
had steeper slopes of the concentration-effect curves for meflo-
quine, lumefantrine and artesunate, whereas they were marginally
shallower in the chloroquine assay (File S2).
Simulation Study Comparing Standard Two-stage and
Nonlinear Mixed-effects Methods for Detecting in vitro
Correlates
To assess the power of detecting significantly important shifts in
the dose response curve associated with specific parasite genotypes
a pseudo-simulation study was conducted using hypothetical study
samples of 25, 50 or 100 isolates from a population of wild type
isolates where the prevalence of two or more copies was 39% for
mefloquine datasets and 33% for lumefantrine datasets.
For both mefloquine and lumefantrine the proportions of
studies where the shift associated with genotype was significant was
similar for both statistical approaches (see Table 4). As expected
the statistical power increased with study size (number of isolates).
The effect of pfmdr1 amplification was more readily apparent for
mefloquine, where almost studies of all sample sizes as low as 25
were able to detect a statistically significant relationship. The
magnitude of the shift associated with pfmdr1 amplification was
lower with lumefantrine (1.8 fold vs 2.6 for mefloquine) in the
population of isolates, and a corresponding higher sample size
(minimum 100 isolates) was required to detect a genotype effect.
When an exclusion criterion based on the precision of the EC50
was applied (CV.15%), the statistical power of the STS fell below
that of the nonlinear mixed-effects modelling in which all isolates
were analysed in the model simultaneously. This loss in statistical
power was not observed for mefloquine where the relative effect
size of genotype group on EC50 was 2.6-fold but was observed for
lumefantrine which had an effect size of 1.8 fold; the absolute loss
in statistical power ranged from 4 to 10% for sample sizes of 25, 50
and 100.
Statistical Power for Future in vitro Studies
Figure 2 presents the statistical power calculated using formulae
for a two-sample comparison of the geometric mean of EC50
between two genotype groups. The figure highlights that for
genotype groups with a low prevalence (e.g. 10%, similar to what
was observed in this study population for single copy with
mutation at positions 86Y or 1042D) a larger number of isolates
would be required to achieve 80% statistical power for detecting a
genotype effect of 1.5 fold (430 total isolates required of which 43
will have genotype group1 and 387 genotype group2), 2 fold (150
total isolates) and 2.5 fold (80 total isolates). As the prevalence of
genotype group increases the total sample size required to achieve
80% statistical power decreases, however, to detect a genotype
effect of 1.5 fold (which may be of clinical importance) 245 isolates
are required if the prevalence of genotype is 20%, 174 isolates if
prevalence is 33% and 156 isolates if the prevalence is 50%.
Discussion
The primary aim of in vitro drug susceptibility testing of
Plasmodia is to derive estimates of drug activity independent
Figure 2. Statistical power by sample size for a comparison of EC50 (geometric mean) between two genotypes.
doi:10.1371/journal.pone.0069505.g002
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from the host and pharmaceutical factors known to confound
in vivo efficacy studies. Several in vitro approaches have been
established and validated although all remain vulnerable to a
variety of methodological factors that are manifest in inherent
within- and between- assay variability. In the current study data
from a large number of clinical isolates of P. falciparum from the
western border of Thailand were used to define the correlation of
in vitro drug susceptibility of four antimalarial drugs with
polymorphisms of the pfmdr1 gene, known to be a key determinant
of multidrug resistance [11,12]. Our results provide precise
estimates of the shifts in drug susceptibility confirming previous
observations that single nucleotide polymorphisms of pfmdr1 are
associated with decreased susceptibility to chloroquine but
increased susceptibility to artesunate, mefloquine and lumefan-
trine. Whereas increased pfmdr1 copy number was associated with
reduced susceptibility to artesunate, mefloquine and lumefantrine.
The main focus of the study was to compare two statistical
approaches for estimating drug susceptibility parameters and
assess their relative merits for defining between-isolate variability
and validating putative molecular markers of antimalarial drug
resistance. Our results demonstrate that the STS approach and
nonlinear mixed-effects modelling provided very similar popula-
tion estimates of EC50s, however the STS was particularly
vulnerable to exclusion of isolates with poor precision. Between
15–28% of isolates were excluded from the STS analysis and since
these isolates were more likely to be highly resistant isolates, the
inevitable consequence was an under-estimation of the population
mean EC50.
The in vitro data used in this study were derived from rich
balanced designs compared to the sparse and unbalanced designs
commonly observed for anti-malarial pharmacokinetic studies
[18–20]. Separation of the within and between-isolate variance
components in the nonlinear mixed-effects model provided
minimal reductions in the between-isolate variability for the
model parameters of three of the four drugs assessed, therefore the
method did not result in greater statistical power for detecting the
genotype effect on EC50.
In the nonlinear regression analyses using the STS approach the
lower precision of the EC50 estimates was likely an artefact of the
design of the in vitro experiment in which doubling dilutions of
drug concentrations is applied, resulting in fewer measurements
and larger intervals at higher drug concentrations [5]. Ideally such
isolates should be retested with a higher series of drug dilutions.
However, without culture adaptation of the parasite this is usually
not feasible. Instead such isolates are often simply excluded from
the STS approach, with inevitable reduction in the estimate of the
overall population EC50 and the possibility of missing the early
detection of resistance emergence. Although nonlinear mixed-
effects modelling cannot overcome inclusion criteria for the assay
itself, it does offer advantages over the STS approach by including
all isolates in the analysis simultaneously to ensure each isolate
contributes some information towards estimation of the parame-
ters. In this approach the within-isolate variability is determined,
thus, drug susceptibility estimates are derived after controlling for
lab covariates such a parasite staging, assay duration and different
batches of drug plates [21]. Further, those isolates with less reliable
individual data (e.g. resistant isolates with no measurements
between the concentrations associated with maximum and
minimum effect) do not contribute the same amount of
information as other isolates (i.e. not all isolates are weighted
equally in the model). Conversely the STS approach weights the
individual isolate-specific estimates equally. This can be problem-
atic since it has been shown in the separate isolate-specific
nonlinear regressions (i.e. stage 1 of the analysis which takes no
account of the other isolates in the population) that the most
resistant isolates tend to have EC50s overestimated as curve fitting
estimates the EC50 to be approximately the mid-point between two
concentrations with very different effect measurements [5].
The nonlinear mixed-effects modelling approach allowed a
comprehensive analysis of the in vitro – molecular correlation for
four major antimalarial drugs. Our findings confirm the role of
pfmdr1 copy number and reduced drug susceptibility to meflo-
quine, lumefantrine and artesunate [10–12,22], the effect ranging
from 63 to 188%. Whereas an increase from 2 to 3 or more copies
resulted in further increments of mefloquine and artesunate this
was not apparent for lumefantrine. We also estimated the change
in both the EC50 and slope of the effect-concentration curve due to
single nucleotide polymorphisms at 86Y and 1042D. These
mutations occurred almost entirely in isolates with a single copy
of pfmdr1, and were associated with a modest increase in the EC50
of chloroquine (44 to 48%). Such estimates can be used for
predictions of isolate specific effect-concentration profiles for
different genotype groups, and included in within-host pharma-
cokinetic-pharmacodynamic models [23] and population level
anti-malarial resistance models [24].
Our results highlight the challenges of validating candidate
markers of drug resistance. The power to detect statistical
significance depends upon the shift in the dose response curve,
and the prevalence of the genotype in the population. There may
be a tendency to dismiss important correlates that are confounded
by inadequate sample size or sample bias. Our sample size
calculations demonstrate that in order to achieve 80% power to
detect an in vitro – molecular effect of a genetic mutation with a
prevalence of 10% and a 1.5 fold shift in the EC50, a sample size of
430 isolates would be required. Whereas a mutation with a greater
effect such as pfmdr1 copy number on mefloquine sensitivity would
be detected with a much smaller sample size (eg only 25 isolates
required for an effect size of 2.5 fold and a prevalence of genotype
in the population of 50%).
In conclusion, our comparison of the conventional STS
approach versus the more sophisticated nonlinear mixed-effects
modelling, for the analysis of in vitro drug susceptibility data, did
not demonstrate any major advantage of applying nonlinear
mixed-effects modelling providing data were generated from
multiple drug concentrations around the EC50, over the most
dynamic part of the dose response curve. However, when sporadic
isolates with high resistance and low precision were present within
a parasite population the nonlinear mixed-effects model estimates
were likely to be less biased, and provide greater power at
detecting in vitro - molecular correlates of candidate molecular
markers of drug resistance.
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